Filtered By:
Specialty: Endocrinology
Condition: Heart Failure
Education: Study
This page shows you your search results in order of relevance. This is page number 4.
Order by Relevance | Date
Total 271 results found since Jan 2013.
Cardiovascular Risk Associated with Acarbose versus Metformin as the First-line Treatment in Patients with Type 2 Diabetes: a Nationwide Cohort Study.
Conclusion: Our data do not support that acarbose has a cardio-protective effect similar to metformin as a first-line anti-diabetic agent.
PMID: 25555040 [PubMed - as supplied by publisher]
Source: Diabetes Metab - January 2, 2015 Category: Endocrinology Authors: Chang C, Chang Y, Lin J, Chen S, Chuang L, Lai M Tags: J Clin Endocrinol Metab Source Type: research
Preventable Major Cardiovascular Events Associated With Uncontrolled Glucose, Blood Pressure, and Lipids and Active Smoking in Adults With Diabetes With and Without Cardiovascular Disease: A Contemporary Analysis.
CONCLUSIONS: Additional attention to traditional CV risk factors could yield further substantive reductions in CV events and mortality in adults with diabetes.
PMID: 25710922 [PubMed - as supplied by publisher]
Source: Diabetes Care - February 20, 2015 Category: Endocrinology Authors: Vazquez-Benitez G, Desai JR, Xu S, Goodrich GK, Schroeder EB, Nichols GA, Segal J, Butler MG, Karter AJ, Steiner JF, Newton KM, Morales LS, Pathak RD, Thomas A, Reynolds K, Kirchner HL, Waitzfelder B, Elston Lafata J, Adibhatla R, Xu Z, O'Connor PJ Tags: Diabetes Care Source Type: research
Outcomes after hypertensive crisis: Comparison between diabetics and nondiabetics
Conclusion Hypertensive crisis is associated with a markedly increased risk for subsequent cardiovascular morbidity and mortality, especially among diabetics who present with heart failure.
Source: IJC Metabolic and Endocrine - March 15, 2015 Category: Endocrinology Source Type: research
Preventable Major Cardiovascular Events Associated With Uncontrolled Glucose, Blood Pressure, and Lipids and Active Smoking in Adults With Diabetes With and Without Cardiovascular Disease: A Contemporary Analysis
CONCLUSIONS
Additional attention to traditional CV risk factors could yield further substantive reductions in CV events and mortality in adults with diabetes.
Source: Diabetes Care - April 23, 2015 Category: Endocrinology Authors: Vazquez-Benitez, G.; Desai, J. R.; Xu, S.; Goodrich, G. K.; Schroeder, E. B.; Nichols, G. A.; Segal, J.; Butler, M. G.; Karter, A. J.; Steiner, J. F.; Newton, K. M.; Morales, L. S.; Pathak, R. D.; Thomas, A.; Reynolds, K.; Kirchner, H. L.; Waitzfelder, B. Tags: Cardiovascular and Metabolic Risk Source Type: research
Cardiovascular risks associated with second‐line oral antidiabetic agents added to metformin in patients with Type 2 diabetes: a nationwide cohort study
ConclusionThere were no differences in overall cardiovascular risks among several add‐on second‐line oral antidiabetic agents; however, glinide plus metformin and α‐glucosidase inhibitors plus metformin combination therapies might be associated with lower risks of acute myocardial infarction.This article is protected by copyright. All rights reserved.
Source: Diabetic Medicine - May 1, 2015 Category: Endocrinology Authors: Y.‐C. Chang, L.‐M. Chuang, J.‐W. Lin, S.‐T. Chen, M.‐S. Lai, C.‐H. Chang Tags: Research Article Source Type: research
Acute Kidney Injury Predicts Major Adverse Outcomes in Diabetes: Synergic Impact With Low Glomerular Filtration Rate and Albuminuria
CONCLUSIONS
AKI, low eGFR, and elevated albuminuria, separately or together, are compelling biomarkers of major adverse outcomes and death in diabetes.
Source: Diabetes Care - November 24, 2015 Category: Endocrinology Authors: Monseu, M.; Gand, E.; Saulnier, P.-J.; Ragot, S.; Piguel, X.; Zaoui, P.; Rigalleau, V.; Marechaud, R.; Roussel, R.; Hadjadj, S.; Halimi, J.-M.; for the SURDIAGENE Study Group Tags: Pathophysiology/Complications Source Type: research
Association of 1,5-Anhydroglucitol With Cardiovascular Disease and Mortality
In diabetes, low concentrations of the biomarker 1,5-anhydroglucitol (1,5-AG) reflect hyperglycemic excursions over the prior 1–2 weeks. To the extent that hyperglycemic excursions are important in atherogenesis, 1,5-AG may provide independent information regarding cardiovascular risk. Nonetheless, few studies have evaluated associations of 1,5-AG with long-term cardiovascular outcomes in a population-based setting. We measured 1,5-AG in 11,106 participants in the Atherosclerosis Risk in Communities (ARIC) study without cardiovascular disease at baseline (1990–1992) and examined prospective associations with co...
Source: Diabetes - December 22, 2015 Category: Endocrinology Authors: Selvin, E.; Rawlings, A.; Lutsey, P.; Maruthur, N.; Pankow, J. S.; Steffes, M.; Coresh, J. Tags: Complications Source Type: research
Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular events, death, and major safety outcomes in adults with type 2 diabetes: a systematic review and meta-analysis
Publication date: Available online 18 March 2016 Source:The Lancet Diabetes & Endocrinology Author(s): Jason H Y Wu, Celine Foote, Juuso Blomster, Tadashi Toyama, Vlado Perkovic, Johan Sundström, Bruce Neal Background In patients with type 2 diabetes, sodium-glucose cotransporter-2 (SGLT2) inhibitors are known to reduce glucose concentrations, blood pressure, and weight, but to increase LDL cholesterol and the incidence of urogenital infections. Protection against cardiovascular events has also been reported, as have possible increased risks of adverse outcomes such as ketoacidosis and bone fracture. We a...
Source: The Lancet Diabetes and Endocrinology - March 19, 2016 Category: Endocrinology Source Type: research
Intensive Diabetes Treatment and Cardiovascular Outcomes in Type 1 Diabetes: The DCCT/EDIC Study 30-Year Follow-up
CONCLUSIONS
Intensive diabetes therapy during the DCCT (6.5 years) has long-term beneficial effects on the incidence of cardiovascular disease in type 1 diabetes that persist for up to 30 years.
Source: Diabetes Care - April 20, 2016 Category: Endocrinology Authors: The Diabetes Control and Complications Trial (DCCT)/Epidemiology of Diabetes Interventions and Complications (EDIC) Study Research Group Tags: Cardiovascular Disease and Diabetes Source Type: research
Cardiovascular and Other Outcomes Postintervention With Insulin Glargine and Omega-3 Fatty Acids (ORIGINALE)
CONCLUSIONS
During >6 years of treatment followed by >2.5 years of observation, insulin glargine had neutral effects on health outcomes and salutary effects on metabolic control, whereas omega-3 fatty acid supplementation had no effect.
Source: Diabetes Care - April 20, 2016 Category: Endocrinology Authors: ORIGIN Trial Investigators Tags: Cardiovascular Disease and Diabetes Source Type: research
SGLT2 Inhibitors and Cardiovascular Risk: Lessons Learned From the EMPA-REG OUTCOME Study
Although cardiovascular (CV) mortality is the principal cause of death in individuals with type 2 diabetes (T2DM), reduction of plasma glucose concentration has little effect on CV disease (CVD) risk. Thus, novel strategies to reduce CVD risk in T2DM patients are needed. The recently published BI 10773 (Empagliflozin) Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients (EMPA-REG OUTCOME) study demonstrated that in T2DM patients with high CVD risk empagliflozin reduced the primary major adverse cardiac event end point (CV death, nonfatal myocardial infarction, nonfatal stroke) by 14%. This beneficial eff...
Source: Diabetes Care - April 20, 2016 Category: Endocrinology Authors: Abdul-Ghani, M.; Del Prato, S.; Chilton, R.; DeFronzo, R. A. Tags: Cardiovascular Disease and Diabetes Source Type: research
Sex Differences in the Effect of Type 2 Diabetes on Major Cardiovascular Diseases: Results from a Population-Based Study in Italy.
Authors: Ballotari P, Venturelli F, Greci M, Giorgi Rossi P, Manicardi V
Abstract
The aim of the study is to assess sex difference in association between type 2 diabetes and incidence of major cardiovascular events, that is, myocardial infarction, stroke, and heart failure, using information retrieved by diabetes register. The inhabitants of Reggio Emilia (Italy) aged 30-84 were followed during 2012-2014. Incidence rate ratios and 95% confidence intervals were calculated using multivariate Poisson model. The age- and sex-specific event rates were graphed. Subjects with type 2 diabetes had an excess risk compared to...
Source: International Journal of Endocrinology - March 21, 2017 Category: Endocrinology Tags: Int J Endocrinol Source Type: research
Cardiovascular safety of vildagliptin in patients with type 2 diabetes: a European multi ‐database, non‐interventional post‐authorization safety study
Abstract
This non‐interventional, multi‐database, analytical cohort study assessed the cardiovascular (CV) safety of vildagliptin vs. other non‐insulin antidiabetic drugs (NIADs) using real‐world data from five European electronic healthcare databases. Patients with type 2 diabetes aged ≥18 years on NIAD treatment were enrolled. Adjusted incidence rate ratios (IRRs) and 95% confidence intervals (95% CIs) for the outcomes of interest (myocardial infarction [MI], acute coronary syndrome [ACS], stroke, congestive heart failure [CHF], individually and as a composite) were estimated using negative binomial regressio...
Source: Diabetes, Obesity and Metabolism - March 24, 2017 Category: Endocrinology Authors: R. Williams, F. de Vries, W. Kothny, C. Serban, S. Lopez ‐Leon, C. Chu, R. Schlienger Tags: BRIEF REPORT Source Type: research
Hypoglycaemia seriousness and weight gain as determinants of cardiovascular disease outcomes among sulfonylurea users
ConclusionsThis study provides evidence of increased CVD risk associated with hypoglycaemia, especially serious hypoglycaemia events. While associations were attenuated with non‐serious hypoglycaemia, the results were suggestive of a potential increased risk.
Source: Diabetes, Obesity and Metabolism - May 1, 2017 Category: Endocrinology Authors: Anthony P. Nunes, Kristy Iglay, Larry Radican, Samuel S. Engel, Jing Yang, Michael C. Doherty, David D. Dore Tags: ORIGINAL ARTICLE Source Type: research
Thyroid Function, Cardiovascular Risk Factors, and Incident Atherosclerotic Cardiovascular Disease: The Atherosclerosis Risk in Communities (ARIC) Study.
Conclusions: Hypothyroidism is associated with hyperlipidemia, but the magnitude is small in mild chemical hypothyroidism, and cardiovascular outcomes are similar between thyroid function groups.
PMID: 28605456 [PubMed - as supplied by publisher]
Source: The Journal of Clinical Endocrinology and Metabolism - June 12, 2017 Category: Endocrinology Authors: Martin SS, Daya N, Lutsey PL, Matsushita K, Fretz A, McEvoy JW, Blumenthal RS, Coresh J, Greenland P, Kottgen A, Selvin E Tags: J Clin Endocrinol Metab Source Type: research
